Acepodia said it received FDA IND clearance for ACE-723, a GPC3-targeted dual-payload antibody-drug conjugate. The company plans to begin a Phase I study in patients with unresectable or metastatic hepatocellular carcinoma, where GPC3 has remained a notable target for ADC development. The clearance places ACE-723 into clinical testing focused on early safety and dose exploration, with typical translational objectives including target engagement and preliminary activity signals. The investigational start adds to the crowded HCC ADC landscape, where differentiation will depend on payload potency, linker behavior, and tumor selectivity. For clinicians, the launch provides another potential option in a setting with limited outcomes and ongoing unmet need for new targeted modalities.